29 min listen
S1E27 / Convalescent Plasma / Arturo Casadevall & Michael Busch
S1E27 / Convalescent Plasma / Arturo Casadevall & Michael Busch
ratings:
Length:
28 minutes
Released:
Jun 9, 2020
Format:
Podcast episode
Description
Transcript“With penicillin, for example, you needed a few days to begin to get better. With antibodies, these people got better within hours, almost as if the antibody was mediating an antitoxin effect.” - Arturo CasadevallIn today’s episode, our host Dr. Celine Gounder speaks with Arturo Casadevall, Chair of the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, about convalescent plasma, the transfer of antibodies from a disease survivor to a disease patient. They discuss the history of convalescent plasma transfer, how it has been used in the past during other infectious disease outbreaks, such as diphtheria and measles, and how the invention of antibiotics led to the decline of this treatment method in the United States. They also talk about the current research studies being done to test the effectiveness of this treatment method on COVID-19 patients. Our host also speaks with Michael Busch, the Director of the Vitalant Research Institute, about how convalescent plasma transfer is currently being used as a treatment for COVID-19 patients at different stages of infection. They also discuss the process of convalescent plasma donation, something that anyone who has recovered from COVID-19 and now has antibodies can do.Listener Q&A: Should I go on an out-of-state trip with my husband’s family? I am antibody negative, how can I minimize the risk of becoming exposed to COVID-19 on the trip?This podcast was created by Just Human Productions. We're powered and distributed by Simplecast. We're supported, in part, by listeners like you.#SARSCoV2 #COVID19 #COVID #coronavirus
Released:
Jun 9, 2020
Format:
Podcast episode
Titles in the series (95)
S1E11 / Surviving COVID / David Lat: "The other point I made about ventilators is, they're not a panacea. Many patients don't survive them, but I don't think that reduces their importance. I think, if anything, the fact that many patients don't survive means we need to make sure that as many patients as could benefit from them actually get them. I hope that one thing we get out of this crisis is enough of a supply so that, if and when we have a future pandemic like this, we are ready." –David Lat, COVID-19 survivor In today’s episode, Ron Klain and Dr Celine Gounder speak with David Lat, a 44-year-old legal journalist who endured days unconscious on a ventilator to survive COVID-19. Still on a path to recovery, he shares his experience and the impact the disease has had on his family and his career, and how he is making a contribution to research going forward. This episode also includes a first-hand account from a frontline healthcare provider in Michigan, Dr. Scott Regenbogen who c by EPIDEMIC with Dr. Celine Gounder